Capricor Therapeutics Long Term Debt

Capricor Therapeutics (CAPR) currently reports a long-term debt of $14M as of March 2026. That compares with $410M in the prior-year period — down 96.6% year over year. Use the charts on this page to explore Capricor Therapeutics's long-term debt history and peer comparisons.

Capricor Therapeutics's long-term debt decreased from $410M to $14M — a 96.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Capricor Therapeutics reported $14M in long-term debt as of March 2026. That compares with $410M in the prior-year period — down 96.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Capricor Therapeutics, and consider following CAPR for alerts when major investors trade the stock.

Capricor Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CAPR with unrelated industries.